Changing of Prostate Specific Antigen Value in Patients With Covid-19

Changing of PSA With Covid-19

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05009186

Enrollment

100

Registered

2021-08-17

Start date

2020-04-01

Completion date

2021-10-01

Last updated

2021-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19, Prostate Specific Antigen

Keywords

Covid-19, Prostate cancer, Prostate Specific Antigen

Brief summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a worldwide pandemic in over 100 years. The disease caused by this newly discovered virus was called Covid-19. In this study, we aimed to evaluate changing of PSA value in patients with Covid-19.

Detailed description

Patients with positive PCR test results were included in the study. The age of the patient and urea, leukocyte, hemoglobin, platelet, urea, and creatinine values of the patients were recorded. Urinalysis and urine culture were taken from all patients. Acute phase reactants such as sedimentation, C-reaktif protein (CRP), ferritin, and fibrinogen were measured both at the time the patients applied and three weeks after the patient recovered. PSA and free PSA were also measured in the same way. Patients whose symptoms improved and the PCR test result was negative were considered as recovered.

Interventions

OTHERPSA value

We measure PSA value during and after covid-19 infection

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Intervention model description

We measured PSA value during and after Covid-19 infection

Eligibility

Sex/Gender

MALE

Age

45 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Male patients (\>45 and \<70 years of age) positive PCR test results were included in the study

Exclusion criteria

* The patients \<45 and \>70 years of age who described lower urinary tract symptoms who had urinary tract infection who a history of prostate biopsy and previous high level of PSA who history of prostatitis were excluded.

Design outcomes

Primary

Measure	Time frame	Description
PSA value	2 months	prostate specific antigen

Secondary

Measure	Time frame
Ferritin, CRP	2 months

Countries

Turkey (Türkiye)

Contacts

Primary ContactOmer G Doluoglu, Associate Professor

drdoluoglu@yahoo.com.tr+905332157809

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026